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ABSTRACT

GENETIC OVER-EXPRESSION OF CYTOKERATIN 18 IN BOVINE LUTEAL CELLS:
EFFECTS ON INTERMEDIATE FILAMENT FORMATION AND FAS LIGANDINDUCED APOPTOSIS

by
Jennifer J. Forcina
University of New Hampshire, December 2009

The receptor Fas and its ligand, FasL, are implicated in apoptosis
of luteal cells during regression of the corpus luteum (CL). In some cell
types, cytokeratin (CK) 8/18 filaments impair FasL-induced apoptosis.
Here, we determined if genetic over-expression of CK18 filaments in luteal
cells similarly prevents FasL-induced apoptosis. Luteal cell cultures were
prepared from early and late stage bovine CL (day 5 and days 16-18 postovulation, respectively). The cells were transduced with media, mock
vector containing GFP, or a CK18-containing vector, and then exposed to
a cytokine cocktail containing FasL for 24 hours. Transduction of luteal
cells with CK18 vector resulted in CK18 aggregates rather than filaments.
The aggregates did not affect surface expression of Fas or progesterone

viii

production. Moreover, the CK18 aggregates did not prevent FasL-induced
apoptosis. Thus, while successful in transducing primary cultures of
bovine luteal cells with CK18, aggregation of CK failed to prevent FasLinduced apoptosis.

IX

CHAPTER I

LITERATURE REVIEW

Significance of Dairy Cattle Infertility
As a nutritional guide by the USDA, the food pyramid suggests 2-3 servings
per day of milk, yogurt, and cheese products from the dairy industry [1].
According to USDA research, while overall milk consumption has declined from
1909 to 2001 (with whole milk declining but lower fat milks increasing over time),
cheese consumption in the US has increased in the same time period [2].
Current farms often demand high milk production from individual cows while
managing higher numbers of cows per farm [3]. Considering milk production is
reliant upon reproduction, it is important to have reproductively healthy cows to
maintain high milk production while minimizing the costs associated with
pregnancy. While milk production per cow has increased, so has the incidence
of reproductive challenges on the dairy farm [3, 4]. For instance, "silent" estrus,
ovarian cysts, nutritional deficiencies, and environmental factors [5] are all factors
contributing to infertility in cows, which has resulted in reproductive failure as a
major reason for culling dairy cows, [4, 6].
In order to resolve these reproductive issues, it is important to understand
the biological reasons behind them. Reproductive failure can be a consequence
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of problems occurring at the organ, tissue, or cellular levels. Therefore, a solid
understanding of how these defects in biological function develop within the
animal will help provide insight about their treatment.

Estrous Cycle: Dairy Cow
Improvement of fertility in the dairy cow hinges on a thorough understanding
of the reproductive cycle in both normal and abnormal states. The estrous cycle
in mammals consists of the cyclic reproductive state that dominates the life of the
female. The estrous cycle typically involves the recruitment of follicles containing
eggs, or oocytes, the development of these follicles, and the selection of at least
one follicle to ovulate, releasing its oocyte [7], and subsequently forming the
corpus luteum [5]. The corpus lutuem is the structure that hormonally maintains
pregnancy following conception [5]. The estrous cycle of a cow typically is 20-21
days, with ovulation often occurring within 24-30 hours after the onset of estrus
[5, 8, 9]. Recruitment of follicles in cows occurs in waves, with typically 2-3
waves of follicular recruitment during a given cycle [7]. Slight increases in
plasma concentration of follicle stimulating hormone (FSH), which released from
the pituitary gland, results in the selection of a cohort of follicles to begin to
mature beyond the primordial follicle stage, with one follicle eventually exhibiting
dominance [7] (Fig. 1). The remaining follicles undergo atresia, or programmed
follicular death, prior to ovulation, but many follicles become atretic without ever
being recruited to a follicular wave [7]. However, the one follicle selected to
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ovulate is also the structure that eventually results in the formation of the corpus
luteum[5, 8, 10].

Figure 1. Representative diagram of a typical estrous cycle of a cow, including
the lifespan of the corpus luteum and the recruitment of one follicular
wave.
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Ovulation, or the release of the oocyte from the dominant follicle, is a
hormonally controlled event within the ovary. As the dominant follicle matures,
the amount of estradiol it produces increases [7, 8, 11]. A peak in estradiol
secretion by the preovulatory follicle induces a surge in luteinizing hormone (LH)
that triggers ovulation [5, 7, 8, 11]. The surge in estradiol is also responsible for
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the cow exhibiting signs of estrus, or sexual receptivity [7, 8]. After the oocyte is
released, the follicle collapses and its remnants reorganize into the corpus
luteum[10](Fig. 1).
The corpus luteum (CL) is the regulatory endocrine structure that
forms on the ovary after ovulation. The CL consists of several cell types,
including steroid producing (steroidogenic) luteal cells, endothelial cells,
fibroblasts, and macrophages [10, 12-15]. In all mammals, the CL is required to
maintain pregnancy if conception occurs, but its requirement during gestation
varies in length among species. For example, progesterone produced by the CL
is required for approximately the first 45 days of gestation in sheep, and the first
200 days in cows [12]. In some animals, particularly the pig, goat, rabbit and
mouse, the CL is the main source of progesterone throughout gestation, but in
others, such as the sheep, horse, and human, the placenta eventually serves as
the main source of progesterone [11]. The steroid hormone progesterone is the
major secretory product of the CL. It is the hormone that maintains pregnancy by
reducing ovarian follicular activity and by preparing a suitable uterine
environment and suppressing the maternal immune response [11]. However, if
pregnancy does not occur, the CL undergoes spontaneous regression to initiate
the next estrous cycle.

Corpus Luteum
The weight, volume [16], blood flow [5, 10, 12] cellular composition [13, 14],
and functional products [16] of the CL vary throughout its life span. The lifespan
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of the CL is typically divided into three stages: developing, functioning, and
regressing. Additionally, the CL can be referred to as early (day 5 postovulation), mid (day 10-12 post-ovulation), and late (days 16-18 post-ovulation)
stage. In general, the weight and volume of the CL increase during the
developing stage, are maintained throughout the functional stage, and then
decrease as the CL regresses [5, 16] (Fig. 1). In studies describing the cellular
composition of the CL, several investigators determined non-steroidogenic cells
are present in higher quantities overall than steroidogenic cells [13, 14]. The
steroidogenic cells of the CL consist of two different cell types, typically referred
to as small and large steroidogenic cells [10, 11, 13, 14]. These small and large
steroidogenic cells are presumably derived primarily from the thecal and
granulosal cells of the ovulated follicle [11, 17].
The steroidogenic luteal cells are the sources of progesterone secretion
within the CL [10-12], with the large cells providing more than 80% of the
progesterone secreted by the bovine CL at mid-cycle [10]. Conversely, the
small cells produce less basal amounts of progesterone but are the cells that are
responsive to luteinizing hormone (LH) and consequently, increase their
progesterone production [10-12]. There are two types of hormones that
principally influence progesterone production by the CL: luteotropic and luteolytic
hormones. Luteotropic hormones encourage CL growth and progesterone
production, with LH generally recognized as the primary luteotropin in domestic
mammals [5, 10-12, 15]. In contrast, luteolytic hormones provoke the demise of
the CL, with prostaglandin F-2a (PGF2a) serving as the primary luteolytic
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hormone in most non-primate species [5, 10-12, 15, 18, 19]. Regression of the
CL is also referred to as luteolysis and involves decreased function and
deteriorating structure of the tissue [10-12, 19]. When the CL regresses, whether
by natural or induced methods, progesterone production decreases [10-12, 16,
20]. The structure of the CL undergoes a process of involution [11] which
involves the loss of cells composing the CL, in part due to apoptosis [10-12].
Also active in the destruction of the CL are immune cells, particularly
macrophages, which are involved in the phagocytosis of apoptotic cells [11, 12],
suggesting a role for the immune system in structural regression. In support of
this concept, Korzekwa and colleagues [21] used an in vitro co-culture model to
demonstrate that a complete decline in CL function does not occur solely in
response to PGF2a but rather requires additional components resulting from the
different cell types within the CL, such as endothelial cells and immune cells [21].

Immune System and the Corpus Luteum
The study of the CL has been traditionally focused within endocrinology.
Hormones not only regulate the CL but are also produced by it. However, in
recent years the relationship between the immune system and the CL, especially
during luteolysis, has generated a lot of interest. Very rarely do critical
physiological events occur without some level of involvement of the immune
system. However, the extent to which the immune system influences
reproduction, and specifically luteolysis, is still uncertain.
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Several immune cells have been discovered in the ovary, including
macrophages, neutrophils, lymphocytes, eosinophils, and mast cells [22, 23].
Each of these cell types has different roles in immune function by virtue of the
different products they secrete. For example, macrophages invade follicles
undergoing atresia in both the rat [22, 24], human [22, 24], and cow [25]. A
familiar role of macrophages is phagocytosis of cellular debris [26]. Therefore, it
is plausible that macrophages enter atretic follicules to prevent an inflammatory
response within the ovary. In addition, a potential role for macrophages during
ovulation in mice [22], humans [27], sheep [28], rats [29], and pigs [30, 31], is to
inhibit an inflammatory response post-ovulation. Neutrophils also exist in the
ovary in high numbers at the time of ovulation in humans [27], rats [29], sheep
[28], and rabbits [32], where their contents aid in the breakdown of the follicle
wall and the release of the egg [31]. Therefore, immune cells are actively
involved in many processes within the ovary.
A considerable amount of evidence supports the contribution of immune
cells to the function of the CL. Immune cells are found in the CL of many
species, including pigs, cows, rabbits, rats, and humans [22, 23, 27, 29-31, 3346]. Macrophages and lymphocytes reside in the CL throughout its lifespan;
however, their numbers vary among stages of the estrous cycle and between
species [22, 30, 45]. Many studies report an increase in specific immune cells at
the time of luteolysis, particularly macrophages [12, 22, 23, 30, 31, 36, 37, 39,
41-43, 45, 47]. Macrophages appear to have several roles in luteal regression,
including phagocytosis of dying luteal cells [11, 12, 31], production of cytokines,
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particularly tumor necrosis factor-a [31], stimulation of PGF2a within the CL [12],
and inhibition of luteal steroid production via cytokines [12, 22, 48].
While the increase in macrophages in luteal tissue often coincides with
luteal regression, the role of T-lymphocytes in the CL is less clearly understood.
T-lymphocytes serve to destroy target cells, initiate further immune response,
and secrete cytokines, including interferon-y [26, 31]. Some studies indicate Tlymphocytes increase as the CL ages [34, 35, 45], while others report
consistently low numbers throughout the lifespan of the CL [27, 31, 33, 36, 39].
This discrepancy could be due to an inconsistency among the studies in terms of
identifying and enumerating the subsets of T-lymphocytes. For instance, Penny
et al. [34] reported three subsets of T-lymphocytes present in the CL throughout
the cycle, but only two subsets increased in the regressing CL. Inconsistencies
may also be attributable to differences among species. Numbers of Tlymphocytes are reported to increase during regression in the cow [34, 35, 45],
whereas T-lymphocyte numbers remain low during the late luteal phase of
rabbits, rats [31, 33, 39], and humans [27].
Neutrophils are considered first responders to infections, and their roles
include secretion of several chemokines and cytokines to attract other immune
cells to their location [26]. Neutrophils exist in the CL of different species, but
their distribution varies among species [27, 31, 33, 49]. Higher numbers of
neutrophils occur in the early stages of the human and rat CL, remaining
relatively constant as the CL ages in humans [27] while decreasing in the rat [31,
33]. In contrast, neutrophils occur in relatively low numbers in the early porcine

8

CL [31]. Intriguingly, neutrophils are the immune cells that infiltrate the CL in
high numbers coinciding with its demise in the golden hamster [49]. In most
species, the quantity of neutrophils may not be as important to the regression of
the CL as it is to the recruitment of other immune cells that contribute to its
demise.

MHC Molecules
As indicated previously, T-lymphocytes populate the CL throughout the
luteal phase. In order for T-lymphocytes to become activated and exert their
actions, they require presentation of antigen by major histocompatibility complex
(MHC) molecules [50]. MHC molecules exist as class I and class II molecules
and elicit different responses in different subsets of T-lymphocytes [50]. In
general, all cells within the body that have a nucleus express MHC class I
molecules [50]. Therefore, it is not surprising that luteal cells express MHC class
I molecules. However, there is conflicting information about the presence of
MHC class I molecules on luteal cells across the lifespan of the CL. In the
bovine CL, expression of MHC class I molecules remains relatively constant
throughout the luteal phase [43, 51]. In contrast, MHC class I expression in the
human increases in old or regressing CL of the previous menstrual cycle [35].
Unlike MHC class I expression, MHC class II molecules are often found
only on professional antigen-presenting cells [50, 52]. MHC class II molecules
are expressed on luteal cells in rats, cows, and humans [19, 30, 33-35, 42, 43,
51, 53-55]. Within the bovine CL, MHC class II expression increases as the CL
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regresses [19, 34, 51]. Both Benyo et al. [51] and Penny et al. [34] observed an
increase in MHC class li molecules in late stage CL. Additionally, Benyo and
colleagues [51] indicate more luteal cells express MHC class II molecules on day
18 in non-pregnant animals than pregnant animals. In human CL, the number of
cells expressing MHC class II molecules increases with age of the CL [35, 55].
However, in one study the increase occurred during the peak of the secretory
phase [55], while another study observed the initial increase later in the cycle
[35]. The challenges of human studies in this area include relatively low sample
numbers due to availability of tissue and inconsistency in the terminology use to
stage the CL. One role proposed for MHC class II molecules on luteal cells is to
increase T-lymphocyte proliferation, during the regression of the CL [56].
However, lymphocyte numbers do not appear to increase in the regressing CL of
all species, suggesting the expression of MHC class II molecules may have a
less conventional role within the CL of certain species.

CCL2
Once immune cells migrate into the CL and become activated, they
release a variety of molecules, such as cytokines, which elicit a variety of
responses within other cells [50]. Immune cells within the ovary secrete several
cytokines, including interferon-y (IFN-y) and tumor necrosis factor-a (TNFa) [12,
42-44, 57, 58]. A sub-set of cytokines includes molecules called chemokines,
which are low molecular weight peptides that often serve as chemoattractants to
recruit additional immune cells to their location [59-62]. For example, chemokine
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ligand 2 (CCL2) recruits monocytes [60-62] and T-lymphocytes [61], and is
expressed in the CL prior to and during regression [38, 40, 41, 45, 59, 63-66].
Luteolytic hormones induce expression of CCL2, and its secretion is
accompanied by the accumulation of monocytes/macrophages within the CL [38,
40, 41, 59, 63]. Cavicchio et al. [67] demonstrated thatluteal endothelial cells are
a source of CCL2 within the bovine CL and that CCL2 expression is increased by
TNFa and IFNy. Oxygen-derived free radicals, Fas ligand, and metabolites of
apoptosis may also stimulate expression of CCL2 [59]. Hence, it is conceivable
that CCL2 enhances the recruitment of immune cells into the CL from the blood
stream, and that these immune cells, in turn, may be a source of cytokines and
further chemokine expression during luteolysis.

IFNy
T-lymphocytes and macrophages are both sources of IFNy [68],
suggesting IFNy has a role in the CL of many species. In terms of luteolytic
actions, IFNy impairs luteal steroidogenesis [69, 70], enhances prostaglandin
production [71], and exerts cytotoxic effects [31, 71, 72], presumably through
immune-mediated mechanisms. Moreover, IFNy increases the numbers of bovine
luteal cells that express MHC class I and class II molecules [12, 30, 31, 42, 53,
54, 73], indicating immune-mediated mechanisms regulate IFN secretion and
actions. In women, IFNy decreases FSH-induced estradiol secretion [69], but not
human chorionic gonadotropin (hCG)-stimulated estradiol production [70].
Additionally, IFNy decreases both basal and hCG-stimulated progesterone
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production [69, 70] by luteal cells [22, 31]. In the cow, IFNy decreases luteal
progesterone production, but also increases prostaglandin synthesis [30, 42, 53,
71, 73]. In cultured bovine luteal cells IFNy is cytotoxic [31, 71, 72]. This
cytotoxic effect is enhanced by other cytokines, notably TNFa [31, 42, 43, 72-74].
Collectively, these observations substantiate the perception that immune cells
contribute to luteal regression through a variety of mechanisms.

TNFa
As indicated above, TNFa is another cytokine that influences luteal
function and is found within the CL of rats, macaques, and cows [20, 75, 76].
Both endothelial cells [44] and macrophages are sources of TNFa within the CL
[12, 22, 23, 43, 47]. TNFa messenger RNA (mRNA) is evident in the CL
throughout its lifespan [43, 58, 75], but a noticeable increase in relative steadystate concentrations of TNF mRNA is seen in regressing CL of some species,
notably rats, macaques, and cows [20, 75, 76]. Thus, TNFa is present within the
CL of several species and is most evident during luteal regression. Like many
cytokines, the actions of TNFa are dependent upon binding to a specific receptor
[77]. Messenger RNA for both TNF receptors, TNFR1 and TNFR2, has been
demonstrated in the CL of cows [20], rats [76], and macaques [75]. The
presence of both TNFa and its receptors in the CL of several species indicates a
potential role for TNFa in the regulation of the CL.
Physiological roles of TNFa are similar to IFNy, and the two cytokines
often work synergistically. TNF impairs luteal steroidogenesis in cows, rabbits,
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and pigs [69, 73, 78-80] and enhances prostaglandin synthesis in cows [73, 78].
Inhibition of progesterone production has been demonstrated in vitro in bovine
[73, 78] and rabbit luteal cells [79]. However, this inhibition was not seen in vitro
in porcine luteal cells [81], but was demonstrated using a microdialysis system in
this species [80]. TNFa alone fails to inhibit both basal and hCG-stimulated
progesterone production in human luteinized granulosa cells [69, 70]. However,
TNFa inhibits IFNy-stimulated progesterone production by human luteal cells [31,
70]. Additionally, TNFa impairs FSH-induced estradiol production by luteinized
human granulosa cells [69]. TNFa exerts cytotoxic actions on cultured luteal
cells, either alone [82] or synergistically with IFNy [31, 42, 43, 72-74].
Interestingly, in cultures of luteinized human granulosa cells, TNFa maintained
basal levels of progesterone secretion for seven days, which would normally
decrease over the time same period [69], suggesting a supportive role for TNFa
in the human CL. The presence of TNF throughout the lifespan of the CL
indicates it may have diverse roles within the tissue, potentially to enhance its
function prior to enhancing its regression.
TNF is a member of the TNF gene superfamily of protein ligands [83]. All
the proteins in this family are thought to form trimeric structures, and they all
induce clustering of their respective receptors at the cell surface [83, 84]. The
activation of these receptors results in various responses, including some
cytotoxic events and some proliferative events [84]. Another protein that exists in
a trimeric form, and whose structure indicates its place in the TNF family of
proteins, is Fas ligand (FasL) [50, 83-85]. Similar to TNF, FasL exists in both a
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membrane-bound form, as well as a soluble form [85]. FasL is another cytokine
of interest within the CL.

FasL
Several studies indicate FasL is expressed within the CL and influences
luteal function. Roughton and colleagues [86] determined FasL mRNA and
protein are expressed in the rat CL during both pregnancy and the post-partum
period. Importantly, FasL mRNA expression increases prior to luteal regression
(Days 16 to 22 of pregnancy) and later decreases during the postpartum period
(Days 1 to 3 post-partum). Evidently, much of the FasL in the rat CL is derived
from immune cells, particularly CD3+ T-cells [87]. Slot and colleagues [88] further
characterized the localization of FasL within the rat ovary and CL to every stage
of the estrous cycle, with the highest amounts of FasL observed in 1 st and 2 nd
generation CL, but only faint detection in the 3rd generation and later. In addition,
FasL is localized primarily to luteal steroidogenic cells of 1 st generation CL, but
present in patches of white blood cells in subsequent generation CL [88]. In the
macaque, expression of FasL mRNA is highest in the mid-late and late CL
compared to early CL, and FasL protein is present in both granulosal and thecalderived cells at all stages [75]. In the cow, FasL mRNA expression increases
shortly after PGF2a injection, peaks at 12 hours after PGF2a, and remains
elevated 64 hours later [20]. The presence of FasL in the CL of most species
studied thus far has prompted further study of its action with regard to luteal
regression and the apoptosis of luteal cells.
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Apoptosis
Apoptosis is a form of cell death, often called 'programmed cell death'
because it is a highly orchestrated process for the selective elimination of cells
without invoking an inflammatory response [89]. Apoptosis of cells can be
signaled by a variety of stimuli, including both external stressors and conditions
within the cell [89, 90]. There are several characteristics of apoptotic cells that
distinguish them from cells dying by other means of cell death, such as necrosis.
These characteristics include morphological and biochemical criteria, as well as
genetic expression of certain relevant genes [89]. For instance, membrane
blebbing, cell shrinkage, and the formation of apoptotic bodies (containing the
contents of the cell) are all morphological characteristics of apoptotic cells [12,
89-91]. Other markers include the condensation of chromatin within the nucleus,
as well as the biochemical fragmentation of DNA into segments of characteristic
size [12, 89-91]. Genetically, several genes serve as critical control mechanisms
in determining whether or not a cell undergoes apoptosis, and examples include
the genes for Fas, p53, and the bcl-2 family of proteins [89, 90], which consist of
both pro- and anti-apoptotic proteins [50, 92]. In summary, apoptosis is a process
of controlled death within target cells, indicated by certain morphological and
biochemical criteria, as well as genetic regulation. Apoptosis of luteal cells
occurs during regression of the CL, especially in ruminant animals [16, 46, 93,
94], and is intimately linked to the structural demise of the tissue [11].
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Apoptosis and the Corpus Luteum
In 1993, Juengel and colleagues [94] reported one of the hallmark
characteristics of apoptosis within the bovine CL. The characteristic degradation
of DNA into oligonucleosomes was shown for late stage bovine CL and CL
obtained after PGF-induced luteolysis [94]. The fragmentation of DNA occurred
only in regressing CL, in association with decreased progesterone production,
implying that apoptosis occurs concomitantly with the functional loss of the tissue
[94]. In the ewe, similar changes, characteristic of apoptosis, occur in the CL
after PGF2a-induced luteolysis [93]. Specifically, DNA fragmentation occurs 12
hours after PGF2a injection [93]. No evidence of DNA fragmentation was
observed in CL of control ewes until day 14 post-ovulation [93]. Apoptotic cells
have also been identified in the late phase of luteal regression within the
pseudopregnant rat [95], as well as during luteolysis in the golden hamster [49]
and human [46].
In addition to the observation of apoptosis within luteal cells of regressing
CL, many of the genes involved in regulating apoptosis have been investigated in
these cells within different species. Several members of the Bcl-2 family in
particular have been identified in the bovine, human, and rat CL [88, 95-97]. The
anti-apoptotic protein Bcl-2 decreases, while the pro-apoptotic protein Bax
increases, as the CL regresses [88, 95-97]. Evidently, the ratio of Bcl-2 to Bax
ultimately determines the fate of the cell [50, 98]. In both human and rat CL, the
ratio of Bcl-2 to Bax decreases as the CL ages [95, 96], which favors apoptosis
of luteal cells [98]. The Fas death receptor has been identified in the CL of
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several species, including the cow [20, 72, 75, 86, 88, 95, 99], as has its ligand,
FasL, as mentioned previously. Interestingly, in a recent study of the antiapoptotic roles of PGF2(1 in bovine luteal cells, PGF2a had no effect on either Bcl2 or Bax mRNA, or on the ratio of Bcl-2 to Bax, but decreased the induction of
Fas mRNA expression by TNFa and IFNy [100]. Therefore, a least part of the
apopotic role of PGF2a likely involves the Fas pathway. Interactions between Fas
and FasL within the CL is of particular interest to many researchers because
Fas-mediated apoptosis occurs within cells with and without the influence of
mitochondrial activity [91, 101]. The potential exists that Fas-mediated apoptosis
may occur first in CL regression, while involvement with the Bcl-2 family of
proteins utilizing the mitochondria may occur subsequently, as indicated by
research within the bovine CL [20]. Also, several adaptor proteins and regulators
of the Fas pathway are elicited, but the complexity of this pathway is not yet
clearly understood.

FasL/Fas Pathway
Apoptosis is induced by a variety factors involving signal ligands and their
corresponding receptors. These cell surface receptors, called death receptors,
are largely members of the TNFR superfamily, which transmit apoptotic signals
[83, 91, 101, 102]. The members of this death receptor family share a conserved
sequence within their cytoplasmic tails that is termed the 'death domain' that
transduces the apoptotic signal [50, 83, 101, 103]. Examples of receptors within
this family include TNFR1 and Fas/Apo-1/CD95 [50, 83, 91, 101]. The ligands

17

for these receptors belong to the aforementioned TNF superfamily of proteins,
which includes TNF and FasL [50, 83]. In the case of FasL, it binds to its
corresponding receptor, Fas, at the cell surface, which triggers receptor
clustering and the organization of the death domains of the receptors [50, 83, 91]
(Fig. 2). Collectively these molecules form the death-inducing signaling complex
or DISC, which includes the adaptor protein Fas-associated death domain
(FADD), the pro-form of caspase-8 [91, 101, 102], and the potentially inhibitory
cellular FLICE-like inhibitory protein (c-FLIP; see Fig. 1 [91, 101, 103]).
Chinnaiyan and colleagues [104] were among to first to identify FADD as a
critical mediator of the FasL-Fas pathway. Residues 111-170 of FADD are
identical to residues 233-292 of the Fas receptor [104], indicating the potential for
interaction between the two molecules. Indeed, FADD associates with both Fas
and an enhanced cytotoxic Fas mutant in co-precipitation experiments [104], yet
does not associate with a functionally inactive mutant form of Fas. Thus, there is
interaction between the death domains of FADD and Fas, as well as the
presence of a death effector domain on FADD that results in death signaling.
This death effector domain of FADD binds to the pro-form of caspase-8 (FLICE),
which causes cleavage and activation of the enzyme, leading to activation of
other downstream effector caspases [83, 101, 103]. Fas-mediated apoptosis can
follow two possible pathways after activation of caspase-8: 1) cleavage of
caspase-3 directly (type I activation) or 2) indirect cleavage of caspase-3 via the
mitochondrial pathway (type II activation) [91, 101-103]. In either scenario, the
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outcome is activation of caspase-3 and the eventual death of the cell by
apoptosis.

Figure 2. Apoptosis can result from interactions within the FasL/Fas apoptotic
pathway.
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The Fas receptor is itself a fascinating molecule, because of its complexity
of ligand binding and transduction of extracellular signaling. In general, the Fas
receptor is approximately 319 amino acids long, containing a cysteine-rich
extracellular domain, and a transmembrane domain spanning 17 amino acids
[105]. Human Fas (hFas) has a relative molecular weight of 43 kDa [105].
Within murine cells, Itoh and colleagues demonstrated that cells transformed with
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hFas cDNA, and subsequently treated with an activating mouse anti-Fas
antibody, underwent apoptosis as a means of cell death [105], suggesting
aspects of FasL-Fas signaling are evolutionary conserved. In cattle, the Fas
receptor consists of 306 amino acids and has a relative molecular weight of 46
kDa [106]. Comparisons of bovine Fas to human and murine Fas, at the
genomic level, indicate bovine Fas is 73% identical to human Fas and 65%
identical to murine Fas [106]. However, the predicted protein sequence of bovine
Fas is only 57% identical to human Fas and 50% identical to murine Fas [106].
Therefore, while homology exists among Fas receptor family members with
blocks of significant conserved domains, the Fas protein does vary among
species. Species differences must be considered when examining the functional
role of Fas in cell death.

Fas Receptor and the Corpus Luteum
There is more extensive information available about the Fas receptor in
terms of its presence and actions during luteal function than FasL. Fas receptor
mRNA [72, 75, 86, 88, 95, 99] and protein [75, 88] are expressed throughout the
luteal phase in certain species, with increased mRNA expression reported in
bovine CL [20, 72] and increased protein expression in rat CL [86, 88] at the time
of luteal regression. In the rat, Fas protein is localized mostly to the cytoplasm of
luteal cells and is absent from endothelial cells of the CL [86, 91]. Evidence of its
functional role in spontaneous regression of these CL is apparent by inhibiting
luteal apoptosis with an anti-rat Fas monoclonal antibody [86]. Further evidence
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of a Fas-mediated apoptotic pathway comes from the observation that the
staining pattern of pro-caspase-3 is similar to that of Fas with faint, active
caspase-3 staining in early generation CL, followed by extensive staining in late
generation CL [88]. Within the macaque CL, Fas protein is localized to
granulosa-luteal and theca-luteal cells in all stages of the CL, but is not detected
in the stroma or endothelial cells [75]. These studies confirm the presence of Fas
within the CL of certain species, localizing it to luteal cells, but not endothelial
cells or other cell types. Overall, the FasL-Fas system may play a key role in
apoptosis of steroidogenic luteal cells specifically and may also contribute to
luteolysis within certain species.
Studies of the mechanism(s) of action of Fas ligand on ovarian cells
indicate other cytokines enhance FasL-induced effects. Within human
granulosa/luteal cells, Quirk and colleagues [99] discovered that Fas antibody
alone (acting as a Fas agonist) does not induce apoptosis, but requires pretreatment with IFNy to induce 30% apoptosis. Using bovine luteal cells,
Taniguchi and colleagues [72] demonstrated that IFN enhances Fas mRNA
expression and that TNF and IFN synergistically increase steady-state
concentration of Fas mRNA. Interestingly, these authors observed that FasL
alone does not induce apoptosis in mid-cycle bovine luteal cells [72].
Conversely, IFN alone induces apoptosis, but that effect is enhanced with the
addition of TNF [72]. In addition, FasL induced death in cells treated with both
IFN alone and IFN acting synergistically with TNF [72]. The potential exists that
the stage of the CL may affect the susceptibility of the luteal cells to FasL,
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potentially due to the availability of the receptor or perhaps other regulatory
mechanisms within the cells.
Additional molecules thought to influence Fas-mediated apoptosis of luteal
cells include intracellular labile proteins, such as c-FLIP [91] and ceramide [107],
which is released during receptor capping. Cycloheximide (CHX), a protein
synthesis inhibitor, enhances Fas-mediated cell death [108], indicating proteins
produced during the death-signaling cascade regulate the downstream effects of
Fas activation. C-FLIP regulates caspases 8 and 10 and is involved in the
formation of the DISC complex in the Fas signaling pathway [103]. The overexpression of c-FLIP within cells can inhibit their apoptosis [103]. Fas-mediated
signaling also involves ceramide release from the luteal cell membrane, an event
associated with amplification of Fas signal transduction [107]. Pru and
colleagues [107] determined soluble FasL increases ceramide in bovine luteal
cells within 5 minutes of treatment, and this increase is maintained through 60
minutes in culture. Using a ceramide analog, the authors also showed that
ceramide induces cell death in bovine luteal cells, and this death is attributed to
apoptosis [107]. In summary, Fas serves as a mediatior of apoptosis within
luteal cells of several species; however, it does not act alone but rather exerts its
effects through complex interactions likely involving several cytokines and
transduction molecules.
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Mechanisms Regulating Fas Expression and Action
Fas receptor aggregation at the cell surface can occur without FasL-Fas
interaction, a phenomenon previously observed with TNFR1 and TNF [109]. So
what is it that regulates Fas receptor expression and aggregation within cells,
especially when the timing of cell death is critical to the tissue? Feng and
Kaplowitz [110] established that microtubules, a cytoskeletal element, increase
Fas expression at the cell surface of hepatocytes. They experimentally disrupted
the microtubules with colchicine, which increased Fas expression on the cell
surface, but interestingly, decreased cell sensitivity to apoptosis induced by a
Fas agonist [110]. Colchicine also increased Fas mRNA and protein expression
within the cells [110], indicating that microtubules may directly or indirectly
regulate the amount of Fas produced within a cell and may influence the amount
of Fas presented at the cell surface. In 2001, Gilbert and co-workers [111] added
to this body of knowledge about cytoskeletal elements by showing that
cytokeratin (CK) intermediate filaments also regulate Fas expression at the
surface of hepatocytes. In their experiments, Gilbert et al. [111] compared wildtype hepatocytes with hepatocytes from knock-out mice in which cytokeratin
intermediate filaments were absent. They showed that the loss of these
filaments increases Fas-mediated apoptosis via the caspase-3 pathway [111].
The presence of the CK intermediate filaments in wild type mice impaired Fas
translocation from the Golgi apparatus to the surface of the hepatocytes [111]. In
contrast, Fas was present in high quantities on the cell surface in CK-knockout
mice. In fact, both an increased number of cells expressing Fas at their cell
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surface, as well as an increase in Fas density at the cell surface, are observed in
CK-null mice compared to wild type mice [111-113]. These observations suggest
that CK intermediate filaments regulate the localization of Fas within cells.

Cytokeratins
Cytokeratins are a component of the cytoskeleton, which contribute to the
structure and integrity of cells. There are three principle types of filament
systems that comprise the cytoskeleton: microfilaments, microtubules, and
intermediate filaments (IF) [112-116]. Intermediate filaments are intermediate in
size between the other two components [112-116] and, as indicated above, are
thought to influence aspects of Fas-mediated apoptosis. Intermediate filaments
consist of at least five different groups of proteins, including type I and type II
proteins, which are sub-groups of cytokeratins [112, 113]. Cytokeratin (CK)
intermediate filaments are obligate heterodimers of a single type I and type II
cytokeratin [113, 115], meaning that intermediate filaments must consist of at
least one type I CK paired with one type II CK. The molecular weight of
cytokeratins ranges from ~40-68kDa [114, 115]. Type I cytokeratins (CK9-20)
are typically small, acidic, and located on chromosome 17, except for CK18 [USUS]. Type II cytokeratins (CK1-8) are typically large, basic, and located on
chromosome 12 [113-115]. CK18 is located on chromosome 12, adjacent to
CK8 [113]. CK8 and CK18 are found in similar cells and tissues within the body,
and they are the only intermediate filaments found in hepatocytes [114]. Due to
CK8/18 intermediate filaments being the only CK intermediate filaments in
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hepatocytes, these cells allow for investigation into the functions of CK8/18 in
cells. Even though the role of CK8/18 intermediate filaments may differ among
cells, the information attained from studies in these cells may indicate the
potential for similar functions of CK8/18 filaments in other cell types.

Cytokeratins and the Corpus Luteum
CK intermediate filaments have been identified within the CL of women,
cows, and rats [117-120]. While CK18 is one of proteins contained within CK
intermediate filament dimers of the bovine CL [117, 118], CK8 has been
identified as its partner in human [119] and rat [120] CL. As determined by
immunohistochemistry, the amount of cells expressing CK18-containing
intermediate filaments decreases as the bovine CL ages. These results were
confirmed quantitatively by flow cytometry. Specifically, the percentage of CK
positive cells decreased from -33% of the cells in early stage to ~5% in late
stage CL [118]. These results raise the question of whether or not CK
intermediate filaments influence the susceptibility of luteal cells to apoptosis in
the CL similarly to the way they influence apoptosis of hepatocytes in the liver.

Hypotheses
Currently, there is limited information available about the expression of
Fas protein in luteal cells, and specifically, expression at the cell surface.
Similarly, the mechanisms controlling apoptosis of luteal cells via Fas-FasL
interactions are poorly understood. The current study investigated the expression
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of Fas both in and on bovine luteal cells from early and late stage CL and
attempted to determine if CK18 intermediate filaments play a role in regulating
Fas expression. Specifically, this study implements genetic over-expression of
CK18 within bovine luteal cells to assess the effect on FasL-induced apoptosis.
The hypotheses tested were as follows: 1) Total Fas protein will increase from
early to late stage in the bovine CL. 2) Surface expression of Fas will increase
as the CL ages. 3) Over-expression of CK18 filaments will inhibit expression of
Fas at the cell surface. 4) Additionally, over-expression of CK18 filaments will
prevent FasL-induced apoptosis.
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CHAPTER II

GENETIC OVER-EXPRESSION OF CYTOKERATIN 18 IN
BOVINELUTEAL CELLS:
EFFECTS ON INTERMEDIATE FILAMENTFORMATION AND
FAS LIGAND-INDUCED APOPTOSIS
Introduction
Infertility of dairy cows has become a major concern for the dairy
industry [4, 6, 121]. Reproductive abnormalities within a herd result in
increased costs and therefore decreased profits for dairy farmers [4]. A
thorough understanding of the reproductive process from the molecular to
the physiological level is needed to address these concerns. Previous
research supports a strong presence of immune cells in the corpus
luteum (CL) [19, 20, 22, 23, 27, 30, 31, 33-46, 49, 122]. In addition, we
know that 'programmed cell death' or more specifically, apoptosis,
contributes to the demise of the CL through elimination of individual luteal
cells [11,16, 44, 46, 49, 93, 94, 122], and a role for immune cells in luteal
regression has been implicated [12, 19, 20, 22, 31, 35, 44, 48]. However,
there is a general lack understanding of the cellular mechanisms
regulating immune-mediated apoptosis within the CL and how these
mechanisms influence aspects of luteal function.
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Several cell types comprise the tissue of the CL, including steroidproducing (steroidogenic) luteal cells, endothelial cells, fibroblasts,
pericytes, and immune cells [10, 12-15, 44]. Many types of immune cells,
including macrophages, neutrophils, lymphocytes, eosinophils, and mast
cells exist within the CL of many species, including pigs, cows, hamsters,
rabbits, rats, and humans [22, 23, 27, 30, 31, 33-46, 49]. Many of these
studies report an increase in specific types of immune cells at the time of
luteolysis, particularly macrophages [12, 22, 23, 30, 31, 36, 37, 39, 41-45,
47]. Immune cells release a variety of effector molecules, termed
cytokines, which elicit desired responses from a variety of cell types, and
chemokines, which recruit additional immune cells [50]. Within the ovary,
immune cells produce such cytokines as interferon-y (IFN-y), tumor
necrosis factor-a (TNFa) [12, 20, 42-44, 57, 58, 95, 123], and Fas ligand
(FasL) [75, 86-88, 124, 125], and chemokines such as chemokine ligand
2 (CCL2) [60-62]. Many cytokines and chemokines elicit responses in
target cells via interactions with their receptors on the cell surface. For
instance, both TNFa and FasL bind death receptors of the same protein
family and can ultimately initiate cell death within the target cell [83, 85,
101].
FasL mRNA and protein have been identified in the CL of many
species, including the rat, macaque, and cow [20, 75, 86-88]. Within
these species, the Fas receptor has also been identified, as well as in
human CL [44, 72, 75, 86, 88, 91, 95, 99]. Previous studies indicate a
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role for Fas-mediated apoptosis of luteal cells [44, 72, 86, 99] in
regression of the CL. Both Fas mRNA in the cow [20, 72] and Fas
protein in the rat [86, 88, 95] increase at the time of luteal regression. In
addition, DNA fragmentation occurs during luteal regression, indicating
apoptosis of luteal cells in both cows and sheep [16, 93, 94]. Roughton
and colleagues [86] confirmed the role of Fas within the CL as a means
of apoptosis by demonstrating a decrease in apoptosis of luteal cells after
the addition of an anti-rat Fas monoclonal antibody. Other studies have
also demonstrated a role for IFNy and TNFa in Fas-mediated apoptosis
within the CL, either by enhancing the efficacy of Fas agonist antibody or
by increasing Fas mRNA [44, 72, 99].
A relatively unexplored area of research in the ovary the
mechanism(s) regulating Fas expression at the cell surface and the
influence on Fas-mediated apoptosis. Several recent studies of
hepatocytes indicate cytoskeletal elements control the trafficking of Fas
to the cell surface [110-113]. In particular, CK8/18 intermediate filaments
influence the density of Fas receptor on the cell surface [111]. Gilbert
and colleagues [111] utilized knockout mice to manipulate the only
intermediate filament pair found within hepatocytes: CK8/18 [114]. Within
wild-type hepatocytes expressing CK8/18 filaments, Fas was localized to
the Golgi complex, yet within CK8-null hepatocytes lacking those
filaments, Fas migrated in abundance to the cell surface [111]. In
addition, the hepatocytes of CK8-null mice were more susceptible to Fas-
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mediated apoptosis than wild-type mice [111]. CK intermediate filaments
occur in the CL of women, rats, and cows [117-120]. Both CK8 and
CK18 are evident in human [119] and rat CL [120], and CK18-containing
filaments are present in the bovine CL [117, 118]. However, as the
bovine CL ages, the number of cells expressing CK18-containing
intermediate filaments decreases, coinciding with the period of luteal
regression [118].
Several important events occur in the bovine CL as it regresses.
Firstly, as the CL ages, Fas mRNA increases [72]. Secondly, the
structural demise of the CL involves apoptosis of individual steroidproducing luteal cells [11, 16, 44, 46, 49, 93, 94, 122]. Finally, the
abundance of CK18-containing steroidogenic luteal cells decreases in
relation to CL age [118]. A role for the Fas receptor within the CL has
been linked to CL regression [44, 72, 86, 99]. Based upon research with
hepatocytes, a potential role for CK8/18 intermediate filaments to control
Fas receptor expression exists [111]. Could CK18-containing
intermediate filaments within the bovine CL have a similar role in
Influencing Fas receptor expression on luteal cells?
The current study explored the potential for CK8/18 filament
regulation of Fas density on the surface of bovine luteal cells, specifically
focusing on the results of genetic over-expression of CK18. Freshly
dissociated luteal cells from early and late stage CL were assessed for
expression of CK18, total Fas, and surface Fas. An adenovirus vector
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was utilized to genetically over-express CK18 within cultured luteal cells
of early and late stage bovine CL. Effects of CK18 genetic overexpression were assessed in regard to cell function, cellular integrity,
expression of Fas, and responsiveness to FasL-induced apoptosis

Materials and Methods
Reagents
Plastic culture vessels used were Becton-Dickinson (Franklin
Lakes, NJ) purchased through Fisher Scientific (Pittsburg, PA). Glass
slides, coverslips, and sodium citrate were purchased from Fisher
Scientific. Collagenase, type I, was purchased from Worthington
Biochemical Company (Lakewood, NJ). Bovine serum albumin (BSA)
was purchased from MP Biomedicals Inc. (Solon, OH). Ham's F12 and
gentamicin (Gibco) were purchased from Invitrogen (Carlsbad, CA).
Trypsin-EDTA was purchased from MediaTech (Manassas, VA). Fetal
bovine serum (FBS) from Gibco was a gift to the UNH cell culture class.
Hank's Balanced Salt Solution (HBSS), trypan blue, ITS (insulin,
transferrin, selenium; 5[ig/5fxg/5ng/ml_), bovine deoxyribonuclease
(DNase) I, and paraformaldehyde (PFA) were purchased from SigmaAldrich (St. Louis, MO). CO2 tanks were purchased from Airgas (Radnor,
PA). Hydrochloric acid was purchased from EM Sciences (North
Vancouver, British Columbia). Normal goat serum (NGS) was purchased
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from Vector Laboratories (Burlingame, CA). Triton X-100 and Tris base
were purchased from J.T. Baker Chemical Company (now Mallinckrodt
Baker, Inc., Phillipsburg, NJ). DAPI mounting medium was purchased
from both Invitrogen and Vector Laboratories. Bovine interferon-y (IFN),
recombinant human Fas ligand (FasL), and murine monoclonal anti-6x
histidine cross-linking antibody were purchased from R&D Systems
(Minneapolis, MN). Murine tumor necrosis factor-a (TNFa) was
purchased from US Biologicals (Swampscott, MA).

Mixed Luteal Cell Culture
Corpora lutea from early (day 5) and late (day 16-18) stages of the
estrous cycle (ovulation = day 0) were obtained by transvaginal
luteectomy and enzymatically dissociated, as described previously [126].
In brief, pieces of tissue were snap frozen in liquid nitrogen for RNA and
protein analysis. The remaining tissue from the CL was sliced, cut into
small pieces, minced, and dissociated 2-3 times using a collagenase type
I solution (dissolved in Ham's F12 medium containing 200[xL gentamicin
and 0.5 g BSA per 100mL) and a mechanical spinner flask for 1 hour
incubations at 37°C with manual pipetting up and down every 10 minutes.
After each dissociation, cells were carried through a series of rinses in
ice-cold Ham's F12 with gentamicin and centrifuged at 4°C. After the
cells were rinsed, they were counted using a hemocytometer and
assessed for viability via trypan blue exclusion method. The cells were
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seeded into T25 flasks at 1.5x106 viable cells/flask and into 12-well plates
containing acid-washed coverslips at 300,000 viable cells per well and
were cultured in Ham's F12 with 10% FBS and gentamicin overnight at
37°C, 5% C0 2 in air with 95% humidity. After the dissociation and cell
seeding, the remaining freshly isolated cells were filtered through screencap tubes at 1.5x106 viable cells per tube and fixed in 1% PFA for 2 hours
on ice.

Analysis of Freshly Dissociated Cells for CK18 and Fas
Freshly dissociated luteal cells from early (day 5) and late (day 1618) stage bovine CL were diluted to 1.5x106 cells per 300[o,L of Ham's
F12, and 300[j,L was added to the top of the screen cap of each tube.
The cells were centrifuged at 514xg, 4°C for 10 minutes. Within each
tube,

100[AL

of Ham's F12 was added, followed by 400^1. of 2% PFA in

PBS, to essentially fix the cells with a 1% paraformaldehyde solution.
The cells were re-suspended in the tubes, and the tubes were wrapped in
parafilm and incubated on ice for two hours, with occasional flicking.
After the two hours, the cells were either held in the fixative at 4°C until
staining or were centrifuged at 276xg, 4°C for 5 minutes. The
supernatant was poured off, and cells were then rinsed with 4mL PBS.
Subsequently, the cells were centrifuged for 5 minutes at 276xg, 4°C.
This step was repeated, and then cells received 1ml_ of ice-cold 70%
ethanol for permeabilization. These tubes were wrapped in parafilm as
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well and stored at -20°C until staining. Permeabilized cells were used for
total staining of CK18 and Fas, whereas cells remaining in the initial
fixative were used for staining of Fas expression on the cell surface.
For CK18 staining, cells were centrifuged at 276xg, 4°C for 5
minutes, and the supernatant was poured off. The cells were rinsed with
1ml_ PBS containing 0.1% BSA, and centrifuged as described above.
This step was repeated, and then the cells were exposed to either

IOOJAL

of PBS containing 1% BSA (negative control), mouse lgG1-FITC at 1:100
in PBS containing 1 % BSA (isotype control), or mouse anti-human CK18FITC at 1:100 in PBS containing 1% BSA. The tubes containing the cells
were wrapped in parafilm and incubated for 1 hour at 37°C. Afterward,
the cells were rinsed twice in PBS as described prior to staining. The
cells were then held in 0.5ml_ PBS/tube until analyzed on the flow
cytometer.
For Fas staining (both total and surface), the rinses and centrifuge
details were identical to the CK18 staining. For incubation with primary
antibody, however, the cells were exposed to either 100^L PBS
containing 1% BSA, 10% NGS (negative control) or mouse anti-human
Fas antibody (clone CH-11, Millipore) at a 1:25 dilution in PBS containing
1% BSA, 10% NGS. The tubes were subsequently wrapped in parafilm
and incubated overnight at 4°C. These cells were then rinsed twice and
incubated for 1 hour with goat anti-mouse Alexa 488 at 1:100 in PBS
containing 1% BSA and 10% NGS (secondary antibody, Invitrogen) at
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37°C, with the tubes wrapped in parafilm. After the secondary antibody
incubation, the cells were rinsed twice and re-suspended in 0.5ml_ PBS
for flow cytometric analysis. The negative controls, either lgG1-FITC for
CK18 or Alexa-488 secondary antibody only for Fas, were used to set the
fluorescence gating to 1% positive controls prior to analysis. The cells
were recorded on the FL-1 filter at no more than 800 events/second with
a total of 10,000 recorded events. When possible, duplicate tubes per
cow were run for each marker. Graphs were composed using Win-MDI
v.2.9 free software.

Immunoprecipitation and Western Blot Detection of CK8/18
Filaments
To verify that cytokeratin intermediate filaments in the bovine
corpus luteum consist of heterodimers of CK8 and CK18, a small portion
of snap-frozen CL tissue was subsequently prepared for
immunoprecipitation and western blot analysis. Briefly, the snap-frozen
tissue was homogenized in 1.5 ml immunoprecipitation lysis buffer (50
mM Tris-HCI, pH 8.0, 137 mM NaCI, 2 mM EDTA, 10% glycerol, and 1%
triton X-100; with 10 uL protease inhibitor, 10 uL 0.1 M DTT, and 10 uL
PMSF per ml of buffer just before use) using a mortar and pestle. The
lysate was transferred to a microcentrifuge tube, vortexed briefly, and
then incubated on a rotary shaker for 30 min at 4°C. Subsequently the
lysate was centrifuged and the supernatant, containing the sample,
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transferred to a new microcentrifuge tube. The supernatant was then
pre-cleared by mixing 2 mg of sample in 1 ml volume with 10 uL normal
rabbit serum and 50 ul protein-G Agarose beads (beads were washed
with lysis buffer 5 times prior to use) with gentle shaking at 4°C for 1 hr.
This step was followed by centrifugation at 12,000xg for 30 seconds and
transfer of the supernatant to a new microcentrifuge tube. Ten microliters
(10 uL) of the mouse monoclonal anti-human cytokeratin-18 antibody
(clone CY-90, Sigma) was added to the sample followed by incubation
overnight at 4°C with shaking. Then, 50 uL of pre-washed homogenous
Protein G was added to the sample followed by incubation at 4°C for an
additional hour. The sample was centrifuged at 12,000xg for 30
seconds, the supernatant was carefully removed, and the remaining
pellet, containing the precipitated agarose-antibody-antigen complexes,
was re-suspended and washed with 0.5 ml_ lysis buffer for 5 min at 4°C,
with shaking. This wash procedure was repeated two additional times.
Following the last wash, the agarose pellet was re-suspended in 30 uL of
4X non-reducing sample buffer, 12 uL of reducing buffer, and 18 uL of
ddH 2 0. The proteins were eluted from the beads by heating the
suspension to 95°C for 10 min. For a negative control, 2 uL (2 ug) of nonspecific mouse IgG was used in place of the monoclonal anti-CK18
antibody. The eluted proteins were resolved by SDS-PAGE and then
probed by western blot analysis using a mouse anti-human CK8 antibody
(clone C51, Santa Cruz Biotechnology, Inc., Santa Cruz, CA).
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Adenovirus Transduction and Cytokine Treatment
An adenovirus serotype 5 vector was used for the transduction
experiments. Vectors were obtained from Dana Farber/Harvard Cancer
Center Vector Core Facility (Boston, MA) and contained a bidirectional
cytomegalovirus promoter (CMV; Fig. 3). The early 1 (E1) and early 3
(E3) genes were deleted from the viral vector to incorporate our gene of
interest and to render the virus 'replication-deficient' [127]. The E1 gene
codes for proteins necessary for viral transformation [128]. The E1A
gene is required for activation of all other early genes [127, 128], while
the E1A and E1B genes work together to mediate cellular transformation
by adenovirus [128]. The E3 gene is linked mostly to modulating the host
immune response to adenovirus infection, potentially through binding
MHC peptides [127, 128]. Adenovirus serotype 5 has a 36kb DNA
genome, which allows up to 2kb of foreign DNA to be inserted into it.
However, by deleting the E1 and E3 genes, an insert up to 7kb can be
introduced into the viral genome [127, 128]. These viral vectors can be
generated as high titer stocks and they will infect a broad range of host
mammalian cells, including both dividing and non-dividing cells [127,
128]. In the current study, it is important for the vector to transduce
primary cultures of non-dividing luteal cells.
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Figure 3. General structure of the replication-deficient adenovirus vector
used for the transduction experiments. Adapted from
http://hqti.med.harvard.edu/pp/Ad-BGFP-Cla.Dna [129].
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Capacity -3,250 bp

ITR
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Transduction treatments consisted of no virus (CTL), mock
adenovirus containing the gene coding for green fluorescent protein
(Ad.GFP), and adenovirus containing the gene for GFP, as well as the
target gene coding for the gene for CK18 (Ad.CK18). Adenovirus stocks
of Ad.GFP and Ad.CK18 were diluted appropriately to obtain a multiplicity
of infection (MOI) of 40 for each culture vessel, thereby introducing 40
viral particules/cell into the cultures. Adenovirus vectors were added to
the cultures in minimal fresh media and incubated for 1-1.5 hours at 37°C
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in a humidified atmosphere. After the incubation, new Ham's F12
containing ITS and gentamicin was added to each well (1mL) and flask
(5mL). Cells were incubated for 16-24 hours at 37°C in a humidified
atmosphere (protocol adapted from that provided by Dr. John Davis,
UNMC, Omaha, NE; see appendix).
Following initial culture and transduction, the cells were then either
fixed with 4% PFA or treated with a cytokine cocktail for 24 hours. The
cytokine cocktail consisted of IFN (200 U/mL), TNFa (10ng/mL) [74],
FasL (50ng/mL), and cross-linking antibody (1mg/ml_) [118]. After
administrating the cytokine cocktail, plated cells were counted in 3 fields
of view (FOV) per well to determine viable cells at the initiation of
treatment. After 24 hours of culture, the number of plated cells was
counted again to determine cell viability (3 FOV/well). Subsequently, the
cells were then fixed in 4% PFA for additional cell viability analysis.
Conditioned media was collected for analysis of progesterone production.

Immunostaining of CK18 and Microtubules in Transduced Luteal
Cells
After fixation, the cultures of luteal cells were rinsed with PBS and
subsequently held in PBS at 4°C until staining. The culture vessels were
wrapped with parafilm to prevent dessication. For staining, the cells were
rinsed 3x for 5 minutes each in PBS containing 0.1% BSA and then
treated with PBS containing 3% BSA, 10% NGS, 0.3% Triton X-100
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(blocking/permeabilizing solution) for 1 hour at RT. Immediately
afterward, this solution was replaced with 300jxL primary mouse antihuman CK18 anitbody (clone CY-90, Sigma) at 1:800 dilution or primary
mouse anti-bovine a-tubulin antibody (clone 236-10501 Invitrogen) at
1:200 in PBS containing 1% BSA, 10% NGS, 0.3% Triton X-100. The
cells were incubated with primary antibody overnight at 4°C and placed
on a gently rocking platform. After the primary antibody incubation, the
cells were rinsed 3x for 5 minutes each in PBS containing 0.1% BSA.
For secondary antibody, 300[iL of goat anti-mouse IgG conjugated with
Texas Red (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) at 1:100
dilution in PBS containing 1% BSA, 10% NGS, 0.3% Triton X-100 was
incubated with the cells for 1 hour at 37°C. After incubation with the
secondary antibody, the cells were rinsed 3x for 5 minutes each in PBS
containing 0.1% BSA and mounted onto glass slides using DAPI
mounting medium as a nuclei counter-stain. Cells were imaged using an
Olympus BX51 microscope, Q-imaging camera, and Q-capture v2.8.1
software. Negative controls consisted of cells receiving no primary
antibody followed by secondary antibody dilution.

Immunostaining of Fas Surface Expression on Transduced Luteal
Cells transduced in flasks were rinsed with 5ml_ HBSS modified
without calcium and magnesium ions, followed by 0.5mL trypsin-EDTA
solution added to each flask to release the cells. With the trypsin solution
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still in the flask, 4mL of 4% PFA was added. The cells were fixed for 30
minutes at RT and then poured into new 5mL centrifuge tubes, where
they were fixed on ice for an additional 90 minutes. After fixation, the
tubes of cells were wrapped with parafilm and held in the fixative at 4°C
until the day before staining. The day before staining, the cells were
centrifuged at 146xg for 10 minutes at 4°C, and then re-suspended in
fresh 2-4% PFA. Once re-suspended, the cells were added to screencap tubes and spun at 276xg for 10 minutes at 4°C. Cell pellets resuspended in fresh 2-4% PFA were held on ice for 2 hours prior to
refrigeration (4°C) overnight. The next day, the cells were washed by
centrifuging at 276xg for 5 minutes at 4°C, rinsing with 1ml_/tube PBS
containing 0.1% BSA, and then centrifuging again. The wash steps were
repeated, and the cells were then incubated with 100[xL of primary mouse
anti-human Fas antibody (clone CH-11 antibody, Millipore, Billerica, MA)
at 20mg/ml_ (1:25) in PBS containing 1 % BSA, 10% NGS at 4°C
overnight. After the overnight incubation, cells were rinsed twice in
1ml_/tube PBS containing 0.1% BSA and then incubated with secondary
goat anti-mouse APC-conjugated antibody (Santa Cruz Biotechnology,
Inc.) at 1:200 dilution in PBS containing 1%BSA, 10%NGS for 1 hour at
37°C. After incubation with the secondary antibody, the cells were
washed twice with 1ml_/tube PBS containing 0.1% BSA and finally resuspended in 0.5mL/tube PBS prior to flow cytometric analysis using a
Becton-Dickinson FACSCalibur Flow Cytometer (UNH Instrumentation
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Center). Cells exposed to secondary antibody only were used as the
negative control with gating set at 1% of the cell population. Cells
transduced with Ad.GFP were used to set the 1% GFP positive cells for
GFP analysis. For flow cytometry, 10,000 cells (events) were recorded
for the data set, at a rate of less than 800 events/second using the FL-1
filter for GFP detection and the FL-4 filter for APC detection. Results
were analyzed using Win-MDI v.2.9 free software.

TUNEL Staining of Transduced Luteal Cells Exposed to Cytokine
Cocktail
Luteal cells were stained for apoptosis using the In Situ Cell Death
Kit, TMR red from Roche Applied Science (Indianapolis, IN). Prior to
staining, the cells were rinsed twice with PBS and then fixed for 30
minutes at RT in 4% PFA in PBS. Subsequently, the cells were stained
following the manufacturer's instructions. In brief, the cells were rinsed
twice with PBS, permeabilized for 2 minutes on ice using 1ml_/coverslip
of 0.1% sodium citrate containing 0.1% Triton X-100 (permeabilizing
solution, made fresh), and rinsed twice with PBS. Positive control cells
were then exposed to 0.1mg/mL bovine DNase in 50mM Tris-HCL, pH
7.5, 1mg/mL BSA for 10 minutes at RT. Remaining cells were exposed
to 50mM Tris-HCI, (pH 7.5) simultaneously. The cells were then rinsed
twice with PBS prior to addition of the TUNEL Reaction Mixture.
Following the kit protocol, enzyme solution was diluted 1:10 in the label
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solution and used at 50>L per sample. Negative control cells were
exposed to 50>L of the label solution only. Parafilm was placed on each
sample, and the samples were incubated with the TUNEL Reaction
Mixture for 1 hour at 37°C in a humidified chamber. The cells were then
rinsed 3x with PBS and mounted onto glass slides using DAPI mounting
medium as a nuclei counter-stain. The cells were imaged using QCapture with 3 fields of view per coverslip, with two images from each
side of the well and one image from the center. Overall, there were 3
images/sample, with 2 samples/treatment group, and images were
captured using the 10x objective. The number of TUNEL-positive cells in
each image was quantified by two independent observers who were blind
to the various treatment groups. In addition, the total number of DAPIstained nuclei per image was used to express the results as a percentage
of TUNEL-positive cells relative to the total number of cells. There was
99% agreement in percent of TUNEL-positive cells between the two
observers.

Progesterone Analysis of Conditioned Media
Progesterone in the conditioned culture medium was analyzed
using a Radioimmunoassay (RIA) Progesterone Kit (catalogue #DSL3400) from Beckton Coulter, Inc. (Fullerton, CA). The assay was
performed according to kit protocol, and the coefficent of variation for this
assay was 8.99% with a standard deviation of 3.5
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Analysis of Serum Progesterone
Blood was also removed from the cow prior to luteectomy for
analysis of serum progesterone. Blood was centrifuged at 914xg, 4°C,
for 15 minutes. The supernatant (serum) was removed and stored at 20°C until day of extraction. Serum progesterone was analyzed via RIA
as described previously [130].

Statistical Analysis
For flow cytometric analyses of freshly isolated luteal cells,
experiments included 4-9 different CL replicates/stage. For
immunohistochemical staining, experiments were replicated with 3-4
CL/stage. Apoptosis and cell death data were acquired from a minimum
of 2-3 CL/stage. Flow cytometric analysis of Fas surface staining of
transduced cells was performed on cells from 3 late-stage CL. Analysis
was performed on the means using a one-way analysis of variance
(ANOVA) in the general linear model of Systat 10 (Chicago, IL) with
stage, treatments, and interactions between treatments and stage. When
appropriate, Tukey's multiple comparison test was used to distinguish
between treatment means. If treatments were performed in replicates on
a single CL, the mean of the results was used in the statistical analysis.
Significance is set at P<0.05.
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RESULTS

Cytokeratin-18 Expression in Bovine Luteal Tissue
A previous study initially demonstrated that the number of cells
expressing CK18 decreases as the CL ages [118]. The present study
confirmed these findings with extensive flow cytometric analysis. The
percentage of cells expressing CK18 in sample preparations from early
stage CL was greater than those from late stage CL (Fig. 4a, P<0.05),
averaging 46% ± 3% for early CL and 26% ± 3% for late CL. Early stage
CL were also used to determine whether the CK-containing intermediate
filaments in these cells consisted of heterodimers of CK8 protein
associated with CK18. Western blot analysis with anti-CK8 antibody,
following immunoprecipitation of luteal lysates utilizing anti-CK18
antibody (Fig. 4b), revealed dimerization of CK8 with CK18. In total luteal
lysates, CK8 was readily detectable at the relative molecular weight of 52
kDa (Fig. 4b, lane 1). Immunoprecipitation with a non-specific,
monoclonal IgG resulted in no detection of CK8 (Fig. 4b, lane 2). In
contrast, immunoprecipitation with the monoclonal, anti-CK18 antibody
revealed a relative enhancement of CK8 protein (Fig 4b, lane 3). The
anti-CK18 antibody used here was also utilized for flow cytometric and
immunofluorescent analysis throughout this study.
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Expression of Fas on Bovine Luteal Cells
Freshly dissociated luteal cells from early and late stage CL were
characterized for total Fas expression and Fas expression on the cell
surface (Fig. 5). A higher percentage of luteal cells expressed Fas in
early stage CL compared to late stage CL (Fig. 5a, P<0.05). Moreover,
more cells from early stage CL expressed Fas on the cell surface than
cells of late stage CL (Fig. 5b, P<0.05). A comparison of the percentage
of cells expressing Fas on the cell surface relative to total Fas expression
revealed that cells from early stage CL express the majority of Fas (76%)
on the cell surface (Fig. 5c). A confocal image of a luteal cell revealed
foci of Fas staining (green) largely at the cell surface (Fig. 5d).

Transduction of Cultured Bovine Luteal Cells With CK18-Containing
Adenovirus
The effect of CK18 adenovirus transduction on cultured bovine luteal
cells from early and late stage CL was assessed by fluorescence
microscopy. In early stage CL, GFP was undetectable in vehicle-treated
wells (Fig. 6b), as expected, but clearly evident in cultures exposed to the
mock vector (Ad.GFP) and the CK18-containing vector (Ad.CK18; Figs.
6f and 6j, respectively). Uptake efficiency was assessed by visual
estimation of GFP-positive cells, which was 53.6% and 67.3% for
Ad.GFP and Ad.CK18, respectively. In cultures exposed to Ad.CK18,
transduction resulted in aggregation of CK18 protein rather than over-
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expression of CK18-containing intermediate filaments (Fig. 6k). In
contrast, no aggregation was observed in vehicle and Ad.GFP-treated
cultures (Figs. 6c & 6g, respectively). Rather, CK18 protein was detected
within filamentous structures, as expected. CK18 aggregates were
morphologically distinct from filamentous structures within the luteal cells
and appeared as foci of intense, punctate staining (Fig. 7).
Similar results were observed in cultures using cells of late stage
CL (Fig. 8). That is, GFP was undetectable in control cultures (Fig. 8b),
but was observed in Ad.GFP and Ad.CK18 cultures (Figs. 8f & 8j,
respectively). Adenovirus uptake efficiency was estimated at 44.6% and
51.5% for Ad.GFP and Ad.CK18 cultures, respectively. As before,
aggregates of CK18 protein, rather than over-expression of filaments,
was seen in all Ad.CK18-transduced cultures (Fig. 8k). No CK18containing aggregates were seen in vehicle or Ad.GFP-transduced
cultures (Figs. 8c & 8g, respectively).

Adenovirus Transduction Does Not Affect Microtubule Formation
There was no effect of adenovirus transduction on microtubules in
cultured bovine luteal cells from early (Fig. 9) and late stage CL (Fig. 10).
In all instances, microtubules remained intact and filamentous in control
(Fig. 9c), Ad.GFP- (Fig. 9g), and Ad.CK18-transduced cultures (Fig. 9k)
from early stage CL. Similarly, in cultures from late stage CL,
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microtubules remained intact in control cells (Fig. 10c) and cells
transduced with either Ad.GFP (Fig. 10g) or Ad.CK18 (Fig. 10k).

Effects of Transduction on Fas Surface Expression on Bovine Luteal
Cells
In cultures of bovine luteal cells from late stage CL, transduction with
Ad.GFP and Ad.CK18 impaired Fas surface expression by 18% and
41%, respectively, in a single experiment (Fig. 11a). In subsequent
experiments, however, these trends diminished such that, overall, no
detectable difference in Fas surface expression was observed among the
treatment groups (Fig. 11b, P>0.05). Moreover, there was no effect of
treatment on relative mean fluorescence intensity of Fas expression (i.e.
relative receptor density) in the experiments (Fig. 11c, P>0.05).

Effects of Transduction and Cytokines on Progesterone Production
and Cell Death in Bovine Luteal Cells
Overall, progesterone production was higher in cultures of luteal cells
from late stage CL compared to early stage CL (Figs. 12 and 13, P<0.05).
However, there was no effect of Ad.GFP or Ad.CKI 8 transduction on
progesterone production by these cultures, regardless of stage (Fig. 12
and 13, P>0.05). In cultures exposed to adenovirus (Ad.GFP or
Ad.CKI 8) and then treated with a FasL-containing cytokine cocktail
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(IFN+TNF+FasL), the cytokine cocktail (FasL) increased progesterone
production (P<0.05), but only in cultures from late stage CL (Fig. 13).
Plated cell counts before and after treatment with the cytokine cocktail
revealed that neither CK18 over-expression nor cytokine treatment
affected the percent of cell death (P>0.05, Fig. 14). A TUNEL assay was
utilized to identify apoptotic cells after cytokine treatment (Fig. 15).
Neither transduction nor cytokine treatment affected the percentage of
TUNEL-positive, apoptotic cells (P>0.05, Fig. 15). Similarly, there was no
effect of stage of CL on this outcome (P>0.05, Fig. 15).
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Figure 4. Characterization of cytokeratin intermediate filaments in the
bovine CL using flow cytometric analysis, immunoprecipitation,
and western blot analysis.
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Percentage of bovine luteal cells from early and late stage CL stained
positively for CK18 as detected by flow cytometry (Fig. 4a). More cells
within the early stage CL expressed CK18 than within late stage CL (n=69 CL/stage, P<0.05). Different letters denote significant differences
(P<0.05). Western blot analysis of CK8 expression in total luteal lysate
from early stage bovine CL, as well as following immunoprecipitation with
anti-CK18 antibody. (Fig. 4b). Immunoprecipitation using anti-CK18
antibody enhanced CK8 expression (lane 3) compared to that found in
total luteal lysate (lane 1).
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Figure 5. Fas expression on bovine luteal cells from early and late stage
CL as determined by flow cytometric analysis.
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Freshly dissociated luteal cells from early and late stage CL were
characterized for total Fas and surface Fas expression. A higher
percentage of cells expressed Fas in early stage CL compared to late
stage CL (Fig. 5a). In addition, more cells expressed Fas on their cell
surface in the early stage CL than the late stage (Fig. 5b). Comparison of
the relative percent of cells expressing total Fas (grey bars) in relation to
those expressing Fas on their cell surface (black bars; Fig. 5c). Bars
represent mean ± SEM (n=4-9 CL/stage). Different letters denote
significant differences (P<0.05). Confocal image (Fig. 5d) of luteal cell
fluorescently stained for Fas (green) is shown with propidium iodidecounterstained nucleus (red).
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Figure 6. Fluorescent detection of GFP and CK18 within cultured bovine
luteal cells of early stage CL after adenovirus transduction.
DAPI

GFP

CK18

Merged

Representative fluorescent photomicrographs (40x objective) of bovine
luteal cell cultures from early stage CL following adenovirus transduction
with control media (CTL; Fig. 6a-d), mock vector (Ad.GFP; Fig. 6e-h), or
CK18 vector (Ad.CK18; Fig. 6i-l). GFP present in the cells indicated in
green (Fig. 6b, 6f, 6j). CK18 staining indicated in red (Fig. 6c, 6g, 6k).
Merged images include DAPI (Fig. 6a, 6e, 6i), GFP, and CK18 staining
(Fig. 6d, 6h, 61).
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Figure 7. Example of filamentous and aggregate CK18 staining with
bovine luteal cells.

Representative fluorescent photomicrograph (40x objective) of bovine
luteal cells from late stage CL following transduction with Ad.CK18.
Arrows indicate individual cells demonstrating either filamentous CK18
staining or aggregate CK18 staining (green).
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Figure 8. Fluorescent detection of GFP and CK18 within cultured bovine
luteal cells of late stage CL after adenovirus transduction.
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Representative fluorescent photomicrographs (40x objective) of bovine
luteal cell cultures from late stage CL following adenovirus transduction
with control media (CTL; Fig. 8a-d), mock vector (Ad.GFP; Fig. 8e-h), or
CK18 vector (Ad.CK18; Fig. 8i-l). GFP present in the cells indicated in
green (Fig. 8b, 8f, 8j). CK18 staining indicated in red (Fig. 8c, 8g, 8k).
Merged images include DAPI (Fig. 8a, 8e, 8i), GFP, and CK18 staining
(Fig. 8d, 8h, 81).
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Figure 9. Effect of adenovirus transduction on microtubules within early
stage bovine luteal cells.
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Representative fluorescent photomicrographs (40x objective) of bovine
luteal cell cultures from early stage CL following adenovirus transduction
with control media (CTL; Fig. 9a-d), mock vector (Ad.GFP; Fig. 9e-h), or
CK18 vector (Ad.CK18; Fig. 9i-l). GFP present in the cells indicated in
green (Fig. 9b, 9f, 9j). Microtubule staining indicated in red (Fig. 9c, 9g,
9k). Merged images include DAPI (Fig. 9a, 9e, 9i), GFP, and microtubule
staining (Fig. 9d, 9h, 91).
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Figure 10. Effect of adenovirus transduction on microtubules within late
stage bovine luteal cells.
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Representative fluorescent photomicrographs (40x objective) of bovine
luteal cell cultures from late stage CL following adenovirus transduction
with control media (CTL; Fig. 10a-d), mock vector (Ad.GFP; Fig. 10e-h),
or CK18 vector (Ad.CK18; Fig. 10i-l). GFP present in the cells indicated
in green (Fig. 10b, 10f, 10j). Microtubule staining indicated in red (Fig.
10c, 10g, 10k). Merged images include DAPI (Fig. 10a, 10e, 10i), GFP,
and microtubule staining (Fig. 10d, 10h, 101).
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Figure 11. Effect of adenovirus transduction with either mock vector (Ad.
GFP) or CK18-containing vector (Ad.CK18) on Fas surface
expression in bovine luteal cells of late stage CL.
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Flow cytometric histogram of Fas surface expression on bovine luteal
cells from late stage CL from a single experiment (Fig. 11a). As a result
of three separate experiments, neither treatment with mock vector
(Ad.GFP) nor with CK18-containing vector (Ad.CK18) affected the
number of cells expressing Fas on their cell surface (Fig. 11b, P>0.05).
There was no significant effect on the relative mean fluorescent intensity
of Fas expression on the surface of late stage luteal cells after
adenovirus transduction with either vector (Fig. 11c, P>0.05). Bars
represent the mean ± SEM (n=3 CL). Different letters indicate significant
differences (P<0.05).
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Figure 12. Progesterone production by early and late stage bovine luteal
cells after adenovirus transduction.
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Figure 13. Progesterone production by early and late stage bovine luteal
cells after cytokine treatment following adenovirus
transduction.
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(IFN+TNF+FasL). However, there was no different in progesterone
production by cultured luteal cells transduced by mock vector compared
to CK18-containing vector, regardless of stage. Bars represent mean ±
SEM. Difference letters represent significant differences (P<0.05).
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Figure 14. Effect of cytokine treatment on adenovirus-transduced luteal
cells from early and late stage CL.
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Figure 15. Effect of cytokine treatment subsequent to adenovirus
transduction on percent of TUNEL-positive cells in cultures of
luteal cells dissociated from early and late stage CL.
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Discussion
The current study explored the potential role of CK8/18
intermediate filaments in the trafficking of Fas within bovine luteal cells
and the susceptibility of these cells to FasL-induced apoptosis. To
understand the underlying mechanisms of FasL-induced apoptosis, luteal
cells from early and late stage CL were characterized in terms of the
abundance of CK18-containing intermediate filaments and the expression
of the Fas death receptor. In a previous study [118], we observed a
decrease in cells expressing CK18-containing filaments as the bovine CL
ages. These previous observations have been confirmed in this study.
CK18-containing filaments were expressed in more cells cultured from
early stage CL (Day 5; 46% positive cells) than late stage CL (Day 16-18;
26% positive). The temporal pattern of cellular expression of CK18containing filaments in the CL during the bovine estrous cycle is
consistent with the previous reports [117, 118]. However, there are some
differences among the studies, particularly with the characterization of the
late stage CL. In particular, the current study found an average of 26% of
luteal cells obtained from the CL of heifers and cows expressed CK18
filaments. This differs from a previous study in our laboratory [118] in
which - 5 % of cells dissociated from late stage CL expressed CK18. The
disparity may be in part accounted for by differences in staging the CL,
and quite possibly, developmental differences between heifers and cows.
The current study utilized both heifers and cows, whereas the previous
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studies used only lactating dairy cows. Heifers typically have a shorter
estrous cycle than cows (averaging 20 days as opposed to 21 days for
dairy cows) [9]. Additionally, variation in staging of CL based upon time
of standing estrus or ovulation could vary greatly between heifers and
cows, especially during the latter half of the luteal phase. These
differences could extend to the relative expression of CK18-containing
filaments in the CL at this time.
CK intermediate filaments consist of obligate type l/type II pairs
[112-115, 131]. CK18 forms filaments with CK8 most frequently [113115]. While CK8/18 filaments have been demonstrated in rat [120] and
human [119] CL, until now only CK18 has been identified within the
bovine CL [117, 118]. Immunoprecipitation was used in the current study
to show CK intermediate filaments within the bovine CL consist of a
heterodimer of CK8 and CK18 protein. Collectively, the results suggest
CK8/18 intermediate filaments occur in the CL of several species and
emphasize the potential role of CK filaments in the CL.
Flow cytometric analysis of Fas expression in luteal cells from early
and late stage CL yielded results that were unexpected. Based upon
previous studies [20, 72, 86, 88, 95], we hypothesized that Fas protein
expression would be higher in cells from late stage CL than from early
stage CL. We also hypothesized that the percentage of cells expressing
Fas on their surface would be higher for late stage CL than early stage
CL. However, the results of the current study failed to support these
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hypotheses. A higher percentage of cells from early stage CL expressed
both total Fas and cell surface Fas than cells from the late stage CL.
Several possibilities exist for these observations. Firstly, it is conceivable
that soluble decoy receptors and/or splice variants of Fas exist on luteal
cells, because decoy receptors and splice variants have been detected in
other cell types from both mice and humans [91, 102, 132-134]. It is
possible that some splice variants may be indistinguishable from native
Fas by the methods of detection used in the current study. Secondly, Fas
receptors at the surface of early stage luteal cells may be involved in prosurvival mechanisms [101, 102]. Both the expression of Fas and all the
potential roles of Fas within the bovine CL require further investigation.
The concept that CK8/18 intermediate filaments influence Fas
receptor expression and apoptosis in bovine CL is based upon previous
work conducted with hepatocytes [111]. Gilbert and colleagues [111]
showed that CK8/18 filaments prevent trafficking of Fas from the Golgi
complex to the cell surface. The authors used knockdown studies in
mice to show that the presence of these intermediate filaments prevented
translocation of the Fas receptor to the cell surface, thereby decreasing
susceptibility to Fas-mediated apoptosis. Here, we over-expressed CK18
protein within cultured bovine luteal cells of early and late stage CL to
determine if CK18 filaments have a similar role in the regulation of Fas
movement to the cell surface. We chose to over-express CK18 rather
than its partner, CK8, because evidence suggests that CK18 is degraded
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more quickly than CK8 during filament polymerization [114]. Thus, if
CK18 is the limiting factor for filament formation in luteal cells of late
stage CL, expression of CK18 via adenovirus transduction should reestablish CK8/18 filament formation within the cell. However, overexpression of CK18 instead resulted in CK18-containing aggregates
rather than filaments. These aggregates were not observed in cultures
treated with control media or mock vector, indicating that neither the viral
vector nor GFP expression induced CK18 aggregation. It appears that
CK18 may not be the limiting protein for filament formation. Several
potential explanations for the failure of CK18 to form complete
intermediate filaments exist, including the known short half-life for CK
proteins [135] and the need for filament components in equimolar
amounts [115, 136].
The fact that the CK18 gene introduced via adenovirus vector is
human CK18 may present a problem. However, this is unlikely. Others
have shown CK intermediate filaments form even when each cytokeratin
composing the pair is not from the same species [136]. However, several
in vitro studies indicate a necessity for each CK monomer to be present
in equimolar concentrations [115, 136] An over-abundance of one type of
CK protein may result in the aggregation or degradation of the protein
rather than dimerization with another type of CK. In the current
investigation, we utilized an adenovirus vector containing a
cytomegalovirus promoter. The CMV promoter is a strong, constitutive
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transcription factor capable of inducing high target protein expression
[137]. Hence, CK18 expression in the current study was essentially
excessive and unregulated. Research by Nakamichi et al. [138]
suggested over-expression of CK18 may actually be toxic to cells due to
its tendency to cause CK aggregation. The aggregates also affected
microtubule organization after 2 days of culture [138]. They also
determined that complementary amounts of CK8 suppress this tendency
[138]. We did not observe any adverse effect of CK18 aggregation on
microtubules in the current study. Interestingly, in cells of early stage CL,
both aggregates and filaments were detectable in the same cell. Another
important feature of intermediate filaments is that individual proteins have
a relatively short half-life in vivo, about an hour or less [135]. Future
explorations of over-expression of CK18 should consider two important
factors: the expression of CK8 in equimolar amounts and the potential of
using an inducible promoter.
In spite of the unsuccessful effort to induce CK filament formation in
bovine luteal cells, the protein of interest, CK18, was successfully overexpressed in cultures from both early and late stage CL. This prompted
us to instead determine the effect of CK18 over-expression and
aggregation on the function and viability of luteal cells. Neither the
adenovirus nor the aggregation of CK18 impaired microtubule formation
within the cells, regardless of CL stage. Similarly, neither the vector nor
the aggregates altered progesterone production by the cells. These
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experiments, to our knowledge, are among the first to demonstrate
successful adenoviral transduction and expression in primary cultures of
bovine luteal cells. Therefore, an important finding is that adenovirus
infection alone is not detrimental to cytoskeletal architecture (i.e.
microtubules and intermediate filaments), progesterone production, or
viability. Moreover, we determined CK18 over-expression results in CK
aggregation, but this too is not detrimental to the cells.
A primary focus of this study was to investigate the effects of CK18
over-expression on Fas surface expression in late stage luteal cells. We
observed no noticeable impact on Fas surface expression in these cells
following over-expression of CK18. Neither the percentage of cells
expressing Fas nor the intensity of Fas on the cell surface was affected
by CK18 aggregation. However, while the experiments overall showed
no significant impact of transduction on Fas surface expression, in all
three experiments Ad.CKI 8 treatment resulted in a decrease in Fas
surface expression, ranging from minimal (5.6% decrease in percent of
cells/5.7% decrease in MFI) to substantial (41% decrease in percent of
cells/12.7% decrease in MFI). These results warrant further exploration.
Toivola et al. [116] suggested that CK intermediate filaments may be
involved in protein targeting or localization. Additionally, Inada et al. [139]
provided evidence that CK8/18 filaments sequester an adaptor protein,
TRADD, involved in TNF-induced apoptosis. Subsequent to their
observations regarding CK8/18 and Fas interactions in hepatocytes,
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Gilbert et al. [140] recently demonstrated a role for CK8/18 filaments in
cytochrome c release after Fas activation. Therefore, it remains plausible
that CK18 is an intermediate component in the regulation of Fas
expression at the cell surface and/or Fas-mediated apoptosis.
A further objective of this study was to investigate the effects of
CK18 over-expression on FasL-induced apoptosis of cultured luteal cells.
The combination of IFNy with TNFa induces apoptosis of bovine luteal
cells after 48 hours [74], resulting in up to 50% death [72]. Adding FasL
to the cytokine cocktail results in -85% death [72]. The rationale for this
seemingly synergistic action of cytokines is that IFNy and TNFa enhance
the effect of FasL by enhancing the expression and/or signaling of the
Fas receptor. In order for FasL to induce Fas-mediated apoptosis,
sufficient numbers of Fas receptor must be available at the cell surface to
aggregate, form the DISC, and then initiate intracellular apoptotic
signaling [83, 91, 101]. IFNy and TNFa increase Fas mRNA [72, 100]
and protein [100] in cultured bovine luteal cells, but it is not known
whether these cytokines enhance Fas expression on the luteal cell
surface. Based on results for from the current study, the potential exists
for early stage cells to be more susceptible to FasL-induced apoptosis
than late stage cells. However, the regulation of the Fas receptor in early
stage luteal cells has not yet been fully explored, and neither early nor
late stage luteal cells were more susceptible to cell death.
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In both control and cytokine-treated cells, progesterone production
was highest from late stage luteal cells. Additionally, progesterone
production was increased only in cultures from late stage CL when
exposed to the FasL-containing cytokine cocktail. If late stage luteal cells
are more susceptible to cytokine-induced cell death, then the
progesterone produced may provide a protective mechanism in culture.
A protective role for progesterone in cultures of bovine luteal cells has
been demonstrated previously [100, 141]. Okuda et al. [141] showed that
the addition of a progesterone antagonist decreases cell viability. The
decrease in viability is further enhanced by the addition of FasL, and the
progesterone anatagonist also increases Fas and caspase-3 mRNA
[141]. Additionally, Bowolaksono et al. [100] demonstrated that in
cultures where progesterone was increased due to treatment, the effects
of TNF+IFN+FasL on cell death and Fas mRNA were negated. Perhaps,
FasL may have been effective in our experiments had we controlled for
progesterone production within the cultured media. Further explorations
in this area should consider the effects of progesterone on the cultured
luteal cells.
Overall, this study confirmed CK filament expression is
highest in luteal cells of early stage CL and diminishes as luteal
regression becomes imminent. Moreover, we demonstrated that the CK
filaments consist primarily of CK8 dimerized with CK18. To our
knowledge, this study is the first to characterize expression of Fas on the
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surface of luteal cells and that the temporal pattern of Fas expression
mimics CK18 filament expression. Although this finding is counterintuitive to previous reports in the literature, it directs attention to the need
for further investigation of the regulatory factors of the Fas pathway in this
tissue. Importantly, we discovered adenovirus transduction can be
achieved in primary cultures of bovine luteal cells with good uptake
efficiency and protein expression. No evidence of adenovirus toxicity
was observed. While over-expression of CK18 protein was achieved, we
discovered that aggregation rather than filament formation occurred.
Therefore, it may be necessary to adjust the expression of both CK8 and
CK18 proteins to assess the role of CK8/18 filaments in these cells.
CK18 knockdown is also plausible based upon our ability to transduce
this cell type, and the knowledge that these interventions lead to filament
disruption [114]. Overall, the potential still exists that CK8/18 filaments
influence FasL-induced death of luteal cells. The methods developed
and implemented in this study provide a basis for further investigation of
this possibility.
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Adenovirus Transduction
1. Plate cells the night before in complete media (i.e. with serum) for 80-90%
confluency at the time of transduction.
2. Dilute crude viral stocks (CVL) to desired titer in serum-free media with
pen-strep.
3. Remove media and replace with virus-containing media (1ml per 1X106
cells). Incubate for 1 or 1 and Vz hrs at 37°C, 5%C02, shaking gently
every 15 min (if possible).
4. Remove virus-containing media, and replace with fresh media with 5%
serum and incubate for 16-24 hrs.
5. Remove media and replaced with pre-equilibrated media and cells were
ready for further treatments.
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